Application of human lymphoid cells for the evaluation of antivirals against human adenovirus type 19: Zalcitabine has superior activity compared to cidofovir.
Adenovirus
antiviral
disaster
pandemic
screening
Journal
Antiviral chemistry & chemotherapy
ISSN: 2040-2066
Titre abrégé: Antivir Chem Chemother
Pays: England
ID NLM: 9009212
Informations de publication
Date de publication:
Historique:
entrez:
30
4
2020
pubmed:
30
4
2020
medline:
5
6
2021
Statut:
ppublish
Résumé
Human adenovirus type 19 (HAdV-19) is a major cause of the epidemic keratoconjunctivitis. Outbreaks of keratoconjunctivitis are problematic to human health, especially for infants, the elderly, and immunocompromised individuals. However, the development of anti-HAdV drugs has been hampered by inconvenient screening systems; therefore, development of a simple screening method is highly desirable. In this study, we identified that HAdV-19 can infect a human lymphoid cell line transformed with human T-cell leukemia virus (MT-2 cells). MT-2 cells supported HAdV-19 replication and showed apparent cytopathic effects within five days post-infection. Using a thiazolyl blue tetrazolium bromide (MTT)-based colorimetric assay on MT-2 cells, we were able to detect the anti-HAdV-19 activities of previously reported nucleoside/tide compounds, including (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (cidofovir), 2',3'-dideoxycytidine (zalcitabine) and 3'-deoxy-3'-fluorothymidine (trifluridine). Compared with previous methods, this system represents a more simple and rapid method to screen anti-HAdV-19 agents.
Identifiants
pubmed: 32345035
doi: 10.1177/2040206620921319
pmc: PMC7218274
doi:
Substances chimiques
Antiviral Agents
0
Zalcitabine
6L3XT8CB3I
Cidofovir
JIL713Q00N
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2040206620921319Références
Virology. 1961 Jun;14:234-9
pubmed: 13756521
J Clin Microbiol. 1998 Nov;36(11):3323-6
pubmed: 9774586
Antiviral Res. 1996 Jul;31(3):159-64
pubmed: 8811200
J Clin Microbiol. 1986 Aug;24(2):265-8
pubmed: 3018038
Antiviral Res. 1991 Jul;16(1):11-6
pubmed: 1776874
J Infect Dis. 2005 Feb 1;191(3):396-9
pubmed: 15633099
Cornea. 1994 Sep;13(5):435-9
pubmed: 7995068
Antiviral Res. 1997 May;34(3):113-9
pubmed: 9191018
J Virol Methods. 1988 Aug;20(4):309-21
pubmed: 2460479
ChemMedChem. 2006 Sep;1(9):939-50
pubmed: 16927344
Antiviral Res. 2001 Dec;52(3):281-8
pubmed: 11675145
Cell Chem Biol. 2018 Oct 18;25(10):1268-1278.e3
pubmed: 30174310
Rev Med Virol. 2008 Nov-Dec;18(6):357-74
pubmed: 18655013
Antimicrob Agents Chemother. 2005 Mar;49(3):1010-6
pubmed: 15728896
Cell Mol Biol (Noisy-le-grand). 1993 Jul;39(5):463-7
pubmed: 8397027
Antivir Ther. 2005;10(2):225-9
pubmed: 15865216
Antivir Ther. 2014;19(2):179-89
pubmed: 24162098
Eur J Microbiol Immunol (Bp). 2014 Mar;4(1):26-33
pubmed: 24678403
Antimicrob Agents Chemother. 2019 May 24;63(6):
pubmed: 30962341
Antiviral Res. 2006 Oct;72(1):34-41
pubmed: 16650905
Invest Ophthalmol Vis Sci. 2009 Nov;50(11):5295-9
pubmed: 19516011